Characterizing the sphingomyelinase pathway triggered by PRIMA-1 derivatives in lung cancer cells with differing p53 status

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3271-3283

  Soans, Eroica ^a   Evans, Susan C ^a   Cipolla, Cynthia ^a,b   Fernandes, Elroy ^a,c  

^a OHIO UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Apoptosis; Lung cancer; p53; PRIMA 1; Sphingomyelinase

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; CERAMIDE; CYTOCHROME C; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS 1 DERIVATIVE; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS 8A; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS 8B; PROTEIN BAX; PROTEIN BCL 2; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2,2 BIS(HYDROXYMETHYL) 1 AZABICYCLO(2,2,2,)OCTAN 3 ONE; 2,2-BIS(HYDROXYMETHYL)-1-AZABICYCLO(2,2,2,)OCTAN-3-ONE; CASPASE 3; FUSED HETEROCYCLIC RINGS; HETEROCYCLIC COMPOUND; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCHEMISTRY; CYTOKINE PRODUCTION; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; MOLECULAR MECHANICS; MULTIGENE FAMILY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CELL CYCLE S PHASE; DRUG EFFECT; ENZYMOLOGY; LUNG TUMOR; METABOLISM; PRIMA-1; TUMOR CELL LINE;

APOPTOSIS; LUNG CANCER; P53; PRIMA-1; SPHINGOMYELINASE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CERAMIDES; HUMANS; LUNG NEOPLASMS; S PHASE; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906307532     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Bykov VJ, Issaeva N, Selivanova G and Wiman KG: Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23: 2011-8, 2002.
2. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature medicine 8: 282-8, 2002.
3. Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-55, 1994.
4. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J et al: PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer cell 15: 376-88, 2009.
5. Wang T, Lee K, Rehman A and Daoud SS: PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Biochemical and biophysical research communications 352: 203-12, 2007.
6. Li Y, Mao Y, Brandt-Rauf PW, Williams AC and Fine RL: Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Molecular cancer therapeutics 4: 901-9, 2005.
7. Malki A, Pulipaka AB, Evans SC and Bergmeier SC: Structure-activity studies of quinuclidinone analogs as anti-proliferative agents in lung cancer cell lines. Bioorg Med Chem Lett 16: 1156-9, 2006.
8. Malki A and Bergmeier S: Differential apoptotic effects of novel quinuclidinone analogs 8a and 8b in normal and lung cancer cell lines. Anticancer Res 31: 1345-1357, 2011.
9. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ and El-Deiry WS: BID regulation by p53 contributes to chemosensitivity. Nature Cell Biol 4: 842-849, 2002.
10. Song L, Coppola D, Livingston S, Cress D and Haura EB: Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biology & Therapy 4: 267-276, 2005.
11. Marchesini N and Hannun YA: Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochemistry and cell biology = Biochimie et biologie cellulaire 82: 27-44, 2004.
12. Martin DA, Siegel RM, Zheng L and Lenardo MJ: Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. The Journal of Biological Chemistry 273: 4345-4349, 1998.
13. Makin G and Hickman JA: Apoptosis and cancer chemotherapy. Cell Tissue Res 301: 143-152, 2000.
14. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
15. Fulda S and Debatin KM: Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 4: 569-576, 2004.
16. Fulda S and Debatin KM: Modulation of apoptosis signaling for cancer therapy. Arch Immunol Ther Exp (Warsz) 54: 173-175, 2006.
17. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006.
18. Fulda S and Debatin KM: Apoptosis signaling in tumor therapy. Ann NY Acad Sci 1028: 150-156, 2004.
19. Rich T, Watson CJ and Wyllie A: Apoptosis: the germs of death. Nat Cell Biol 1: E69-71, 1999.
20. Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4, 2000.
21. Oliver L and Vallette FM: The role of caspases in cell death and differentiation. Drug Resist Updat 8: 163-170, 2005.
22. Fischer U, Janicke RU and Schulze-Osthoff K: Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10: 76-100, 2003.
23. Fulda S and Debatin KM: Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23: 6702-6711, 2004.
24. Pucci B, Kasten M and Giordano A: Cell cycle and apoptosis. Neoplasia 2: 291-299, 2000.
25. Smith DM, Gao G, Zhang X, Wang G and Dou QP: Regulation of tumor cell apoptotic sensitivity during the cell cycle (Review). Int J Mol Med 6: 503-507, 2000.
26. Sawada M, Nakashima S, Kiyono T, Nakagawa M, Yamada J, Yamakawa H et al: p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells. Oncogene 20: 1368-1378, 2001.
27. Carpinteiro A, Dumitru C, Schenck M and Gulbins E: Ceramide-induced cell death in malignant cells. Cancer letters 264: 1-10, 2008.
28. Kolesnick RN and Kronke M: Regulation of ceramide production and apoptosis. Annual review of physiology 60: 643-665, 1998.
29. Obeid LM and Hannun YA: Ceramide: a stress signal and mediator of growth suppression and apoptosis. Journal of cellular biochemistry 58: 191-198, 1995.
30. Jarvis WD, Grant S and Kolesnick RN: Ceramide and the induction of apoptosis. Clinical cancer research: an official journal of the American Association for Cancer Res 2: 1-6, 1996.
31. Spiegel S, Foster D and Kolesnick R: Signal transduction through lipid second messengers. Current Opinion in Cell Biology 8: 159-167, 1996.
32. Zborovskaia IB and Tatosian AG: Molecular markers of various stages of nonsmall cell lung cancer development. Molekuliarnaia Biologiia 38: 191-202, 2004.
33. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT et al: Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 114: 3431-3438, 2009.
34. Sica G and Chen L: Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Archivum immunologiae et therapiae experimentalis 47: 275-279, 1999.
35. Leu JI, Dumont P, Hafey M, Murphy ME and George DL: Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nature Cell Biology 6: 443-450, 2004.
36. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes & Development 13: 239-252, 1999.
37. Cheng YJ, Jiang HS, Hsu SL, Lin LC, Wu CL, Ghanta VK et al: XIAP-mediated protection of H460 lung cancer cells against cisplatin. European J Pharmacology 627: 75-84, 2010.
38. Schwandner R, Wiegmann K, Bernardo K, Kreder D and Kronke M: TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase. The Journal of biological chemistry 273: 5916-5922, 1998.
39. Yount GL, Afshar G, Ries S, Korn M, Shalev N, Basila D et al: Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene 20: 2826-2835, 2001.
40. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES et al: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
41. Gaur U and Aggarwal BB: Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochemical Pharmacology 66: 1403-1408, 2003.
42. Hsu H, Shu HB, Pan MG and Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84: 299-308, 1996.
43. Kuai J, Nickbarg E, Wooters J, Qiu Y, Wang J and Lin LL: Endogenous association of TRAF2, TRAF3, cIAP1, and Smac with lymphotoxin beta receptor reveals a novel mechanism of apoptosis. The Journal of Biological Chemistry 278: 14363-14369, 2003.
44. VanArsdale TL, VanArsdale SL, Force WR, Walter BN, Mosialos G, Kieff E et al: Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. Proceedings of the National Academy of Sciences USA 94: 2460-2465, 1997.
45. Imaizumi K, Morihara T, Mori Y, Katayama T, Tsuda M, Furuyama T et al: The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein. The Journal of Biological Chemistry 274: 7975-7981, 1999.
46. Dean EJ, Ward T, Pinilla C, Houghten R, Welsh K, Makin G et al: A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. British J Cancer 102: 97-103, 2010.
47. Riedemann J, Macaulay VM: IGF1R signalling and its inhibition. Endocrine-related Cancer 13: S33-43, 2006.
48. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
49. Budihardjo I, Oliver H, Lutter M, Luo X and Wang X: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15: 269-290, 1999.
50. Grassme H, Schwarz H and Gulbins E: Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem Biophys Res Commun 284: 1016-1030, 2001.
51. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K et al: CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 276: 20589-20596, 2001.
52. Grassme H, Jendrossek V, Bock J, Riehle A and Gulbins E: Ceramide-rich membrane rafts mediate CD40 clustering. J Immunol 168: 298-307, 2002.
53. Gross A, Jockel J, Wei MC and Korsmeyer SJ: Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. Embo J 17: 3878-3885, 1998.
54. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
55. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ: Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139: 1281-1292, 1997.
56. Pan G, O'Rourke K and Dixit VM: Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem 273: 5841-5845, 1998.
57. Barinaga M: Death by dozens of cuts. Science 280: 32-34, 1998.
58. Soans E: Investigating the Molecular Mechanism of Novel Quinuclidinone Derivatives in Lung Cancer Cells with Different p53 Status [Electronic Thesis or Dissertation]. OhioLINK Electronic Theses and Dissertations Center: Ohio University; 2010.